Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia BWolfgang Miesbach, Frank W.G. Leebeek, Karina Meijer et al.|Blood|2017Cited by 300
Clinical severity of haemophilia A: does the classification of the 1950s still stand?I. E. M. DEN UIJL, Kathelijn Fischer, E. P. Mauser Bunschoten et al.|Haemophilia|2011Cited by 244
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 yearJenneke Leentjens, Saskia Middeldorp, Thijs F. van Haaps et al.|The Lancet Haematology|2021Cited by 237
Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysisGeert‐Jan Geersing, Karel G.M. Moons, Nicolaas P. A. Zuithoff et al.|BMJ|2014Cited by 227
How I treat age-related morbidities in elderly persons with hemophiliaP.M. Mannucci, Evelien P. Mauser‐Bunschoten, Roger E. G. Schutgens et al.|Blood|2009Cited by 185